Skip to main content
Close up of a hand using a tablet

Latest News

Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario

February 20, 2025

Apo-Teriparatide Injection ™ is a generic alternative to Forteo®.

Osteoporosis pharmacologic therapies are classified as antiresorptive therapy, which inhibits osteoclastic activity, and anabolic therapy, which stimulates new bone formation. Apo-Teriparatide is an anabolic therapy.

To view more information about provincial and territorial drug coverage visit https://osteoporosis.ca/provincial-territorial-drug-coverage/


OC MAKES THE NEWS – RECENT ITEMS

Dr. Lora Giangregorio Named Canada Research Chair

March 19, 2025
Latest News Dr. Lora Giangregorio Named Canada Research Chair March 19, 2025 The University of Waterloo, Kinesiology and Health Sciences Professor Lora Giangregorio has been awarded a Tier 1 Canada […]

Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario

February 20, 2025
Latest News Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario February 20, 2025 Apo-Teriparatide Injection ™ is a generic alternative to Forteo®. Osteoporosis pharmacologic therapies are classified […]

2024 Gideon A. Rodan Excellence in Mentorship Award

August 16, 2024
Latest News 2024 Gideon A. Rodan Excellence in Mentorship Award Angela Cheung, M.D., Ph.D. is the recipient of the 2024 Gideon A. Rodan Excellence in Mentorship Award which is given […]
© Osteoporosis Canada, 2025
Charitable Registration No. 89551 0931 RR 0001